NICE draft guidance approves pertuzumab for early HER2-positive breast cancer


  • Dawn O'Shea
  • Oncology drug update
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

NICE has published final draft guidance which now recommends pertuzumab (Perjeta) with intravenous trastuzumab and chemotherapy as adjuvant treatment for early HER2-positive breast cancer with lymph node involvement.

In the previous draft guidance, NICE had concluded that the uncertainty in the clinical effectiveness of evidence made the cost-effectiveness estimates for pertuzumab uncertain. Despite taking into account the positive impact on the overall cost of the adjuvant pertuzumab regimen of cheaper biosimilar trastuzumab and a discount to the price of pertuzumab, it could not be recommended as a good use of NHS resources, NICE said.

However, following consultation on the draft guidance, the company (Roche) proposed an improved discount to the price of pertuzumab. They also submitted a revised economic model which included only patients with lymph node-positive disease and used NICE’s preferred, more conservative estimates of how long treatment benefit with pertuzumab will last. The resulting cost-effectiveness estimate was below the NICE threshold of £20,000 per QALY gained and is therefore considered a cost-effective use of NHS resources.

The current opinion is a draft version. The final guidance is expected to be published next month (March 2019).